Holen Sie sich die Stockscreener-App
1.735
1.42%
-0.025
Schlusskurs vom Vortag:
$1.76
Offen:
$1.78
24-Stunden-Volumen:
562.01K
Relative Volume:
0.61
Marktkapitalisierung:
$184.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.64M
KGV:
-4.1055
EPS:
-0.4226
Netto-Cashflow:
$-13.98M
1W Leistung:
+1.46%
1M Leistung:
-0.29%
6M Leistung:
-58.89%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.655
$1.78
1-Wochen-Bereich:
$1.655
$1.82
52-Wochen-Spanne:
$1.58
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Firmenname
Nervgen Pharma Corp
Sektor
Branche
Telefon
-
Adresse
-
Compare NGEN vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
1.735 | 187.29M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-27 | Eingeleitet | H.C. Wainwright | Buy |
Nervgen Pharma Corp Aktie (NGEN) Neueste Nachrichten
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
NGEN: RESTORE Phase 3 trial advances with robust funding and FDA alignment; Q2 net loss widens - TradingView
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Caledonian Record
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NervGen Pharma (NGEN) Institutional Ownership 2026 - MarketBeat
NervGen Pharma (NGEN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
NGEN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals Market Sentiment - benzinga.com
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nervgen Pharma Ord Shs (NGEN) Balance Sheet - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Income Statement - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.640|Chg%:+0.010 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Cash Flow - TradingKey
NervGen Pharma Corp. Revenue Breakdown – NASDAQ:NGEN - TradingView
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.630|Chg%:-0.045 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NGEN Q3 2025 Earnings: Slight EPS Beat Amid Ongoing Pipeline DevelopmentGAAP Earnings Report - dars.gov.et
Certain Common Shares of NervGen Pharma Corp. are subject to a Lock-Up Agreement Ending on 21-JUL-2026. - marketscreener.com
HC Wainwright Lowers Earnings Estimates for NervGen Pharma - MarketBeat
Stock Ratings | HC Wainwright lowered its price target for NervGen Pharma (NGEN) to $15, with a potential upside of 762.07%; KeyBanc raised its price target for Nvidia (NVDA) to $330 - Sahm
H.C. Wainwright cuts NervGen stock price target to $15 on dilution By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
H.C. Wainwright cuts NervGen stock price target to $15 on dilution - Investing.com Nigeria
NGEN Maintains Buy Rating by HC Wainwright & Co. -- Price Target Lowered to $15.00 - GuruFocus
NervGen Pharma (NGEN) Gains Ground: Biotech Stock Holds Above Key SupportRelative Volume - dars.gov.et
NGEN Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Leerink Partners Initiates NervGen Pharma(NGEN.US) With Buy Rating, Announces Target Price $10 - Moomoo
NervGen Pharma (NASDAQ:NGEN) Now Covered by Leerink Partners - MarketBeat
Lobbying Update: $50,000 of NERVGEN PHARMA CORP. lobbying was just disclosed | NGEN Stock News - Quiver Quantitative
If You Invested $1,000 in Nervgen Pharma Corp (NGENF) - Stock Titan
NGEN Q3 2025 Earnings: Narrow EPS Beat Masks Continued Pre-Revenue Stage, Stock Sheds Nearly 7%EPS Consistency Score - dars.gov.et
Breakthrough peptide repairs nerves after spinal cord injury in clinical trial - BioXconomy
NervGen Pharma (NGEN) Q3 2025 Earnings: Small EPS Beat Amid Ongoing Clinical Development and Cash ManagementEarnings Growth Analysis - dars.gov.et
NervGen Pharma(NGEN) Stock Options Chain | Quotes & News - Moomoo
NervGen Pharma Corp. (NGEN) Q3 2025 Earnings: Small EPS Beat as Pipeline Progress Underpins Market ConfidenceOperating Margin Analysis - dars.gov.et
If You Invested $1,000 in Satellos Bioscience Inc (MSCLF) - Stock Titan
NervGen Pharma Corp. (NGEN) Edges Higher: Biotech Stock Tests Support at $2.01 Amid Modest GainsDividend Arbitrage - dars.gov.et
NervGen Pharma Sets Up US$50 Million ATM Equity Program With Leerink Partners - TipRanks
NervGen Pharma remains a Buy after FDA aligns o... - Pluang
NervGen Pharma: I Think The Biggest Risks Are Now Behind It (NASDAQ:NGEN) - Seeking Alpha
NGEN Q3 2025 Earnings: Narrower-Than-Expected Loss Drives Positive Market ResponseProfit Recovery Report - dars.gov.et
NGEN Q3 2025 Earnings: Narrower Loss Surprises, Stock Advances Amid Pipeline FocusGeographic Revenue Trends - dars.gov.et
Enterprise value to revenue forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to book forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Enterprise value to EBIT forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Enterprise value to EBITDA forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
Price to sales forward of NervGen Pharma Corp. – NASDAQ:NGEN - TradingView
NervGen Pharma Corp. Actuals & Estimates (NASDAQ:NGEN) - TradingView
Finanzdaten der Nervgen Pharma Corp-Aktie (NGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):